Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on July 31, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved Kashiv acquisition, clearing a key closing condition under the Purchase Agreement.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders approved Kashiv acquisition, clearing a key closing condition under the Purchase Agreement
- Stock issuance approved for 28,942,108 shares to Kashiv sellers, creating meaningful dilution for existing holders
- Transaction Proposal passed 138,265,079–655,759 among disinterested stockholders
- Stock Issuance Proposal passed 286,714,072–1,791,016, satisfying Nasdaq Listing Rule 5635(a)(2)
- Closing expected in second half of 2026, subject to remaining conditions including regulatory approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.